Marilynn Larkin June 02, 2024 Nearly 2 years after their final infusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for their symptoms, revealed research presented today at ENDO 2024 and published in Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen...
Tag: <span>thyroid eye disease</span>
Post
Thyroid eye disease patients report maintained improvement two years after teprotumumab infusions
JUNE 2, 2024 by The Endocrine Society Credit: Pixabay/CC0 Public DomainMost patients with thyroid eye disease treated with teprotumumab didn’t require additional treatment nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, and published in the journal Thyroid. “Thyroid eye disease is a...
Post
Increased risk of hearing impairment with new thyroid eye disease treatment
THE ENDOCRINE SOCIETY WASHINGTON–More patients than previously reported may experience hearing symptoms such as hearing loss or muffled hearing from a new treatment for thyroid eye disease, teprotumumab (Tepezza), according to a small study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting. Teprotumumab, approved by the U.S. Food and Drug Administration in January...
Post
First FDA-approved drug for thyroid eye disease effective regardless of age, gender
Teprotumumab, the first FDA-approved medicine for thyroid eye disease, provides significant improvement in eye bulging, regardless of patient gender, age or smoking status, according to a study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society. Though it is...